Technical Analysis for RLAY - Relay Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical RLAY trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 6.99% | |
| Oversold Stochastic | Weakness | 6.99% | |
| Bullish Engulfing | Bullish | -1.66% | |
| Pocket Pivot | Bullish Swing Setup | -1.66% | |
| NR7 | Range Contraction | -1.66% | |
| Inside Day | Range Contraction | -1.66% | |
| Wide Bands | Range Expansion | -1.66% | |
| Oversold Stochastic | Weakness | -1.66% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above 10 DMA | about 6 hours ago | |
| Rose Above Previous Day's High | about 7 hours ago | |
| 10 DMA Resistance | about 7 hours ago | |
| Up 10% | about 7 hours ago | |
| Up 1 ATR | about 7 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.0 |
| 52 Week Low | 32.56 |
| Average Volume | 692,670 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 46.93 |
| 20-Day Moving Average | 47.57 |
| 10-Day Moving Average | 44.27 |
| Average True Range | 3.82 |
| ADX | 14.98 |
| +DI | 16.54 |
| -DI | 19.84 |
| Chandelier Exit (Long, 3 ATRs ) | 51.50 |
| Chandelier Exit (Short, 3 ATRs ) | 51.65 |
| Upper Bollinger Band | 55.15 |
| Lower Bollinger Band | 39.99 |
| Percent B (%b) | 0.22 |
| BandWidth | 31.87 |
| MACD Line | -1.72 |
| MACD Signal Line | -0.91 |
| MACD Histogram | -0.8111 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.50 | ||||
| Resistance 3 (R3) | 50.38 | 47.86 | 49.30 | ||
| Resistance 2 (R2) | 47.86 | 46.02 | 47.92 | 48.90 | |
| Resistance 1 (R1) | 45.57 | 44.89 | 46.72 | 45.69 | 48.50 |
| Pivot Point | 43.05 | 43.05 | 43.62 | 43.11 | 43.05 |
| Support 1 (S1) | 40.77 | 41.22 | 41.91 | 40.89 | 38.08 |
| Support 2 (S2) | 38.25 | 40.08 | 38.31 | 37.68 | |
| Support 3 (S3) | 35.96 | 38.25 | 37.28 | ||
| Support 4 (S4) | 36.08 |
